Jerome Bailey

Jerome Bailey joined Longeveron in 2022 from Checkmate Pharmaceuticals (acquired by Regeneron), where he served as senior director of program management. Mr. Bailey brings to the company more than 30 years of operational leadership and program management experience in the biopharmaceutical industry, overseeing clinical trials from Phase 1 through Phase 4 across several therapeutic areas.

As the senior director of program management at Checkmate Pharmaceuticals Mr. Bailey led cross-functional project teams driving multiple oncology programs from candidate selection through clinical development. Before Checkmate Pharmaceuticals, he held roles of increasing responsibility at Parexel, where he led multiple global development programs across several therapeutic areas, including in oncology, hematology, pulmonary, and pediatric rare diseases. He also facilitated the product submission strategy across several major global markets for schizophrenia and hypertension. Prior to Parexel, Mr. Bailey held senior management roles at Applied Clinical Intelligence, Theorem Clinical Research, BDH Clinical Research, Covance, and Eli Lilly. Mr. Bailey began his career as a clinical researcher at Ayerst Laboratories, and later at Hoffman La Roche. Mr. Bailey holds a bachelor’s degree in the biological sciences from Rutgers University.